Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 5, 2010

Microsynth Supplies Sequencing Customers with CLC Bio’s Analysis Software

  • CLC bio is collaborating with Microsynth to support the high-throughput sequencing analyses market in Switzerland. Under the agreement, Microsynth will provide all Swiss customers receiving high-throughput sequencing data with a license for CLC Genomics Workbench for assembly and downstream sequence analyses.

    CLC Genomics Workbench for next-generation sequencing is a cross-platform desktop application with a graphical user-interface. It incorporates an SIMD-accelerated assembly algorithm to help overcome the challenge of analyzing next-generation sequencing data more quickly than it is produced. The Workbench is designed to support and integrate with the rest of a typical next-gen sequencing workflow.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »